Sensei Biotherapeutics to Present at Upcoming Conferences
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage immuno-oncology company, has announced its participation in two upcoming conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 7:00 a.m. ET, delivering a corporate presentation. Additionally, Sensei will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on September 18 at 2:30 p.m. ET.
Both events will be accessible via webcast on the Investors section of Sensei's website, with replays available for approximately 90 days following the presentations. These conferences provide Sensei Biotherapeutics with opportunities to showcase their progress in developing next-generation cancer therapeutics to investors and industry professionals.
Sensei Biotherapeutics (Nasdaq: SNSE), una società di immuno-oncologia in fase clinica, ha annunciato la sua partecipazione a due conferenze che si terranno a settembre 2024. L'azienda presenterà al 26° Annual Global Investment Conference di H.C. Wainwright il 9 settembre alle 7:00 ET, con una presentazione aziendale. Inoltre, Sensei parteciperà a un incontro informale al 2024 Cantor Fitzgerald Global Healthcare Conference il 18 settembre alle 14:30 ET.
Entrambi gli eventi saranno accessibili tramite webcast nella sezione Investitori del sito web di Sensei, con replay disponibili per circa 90 giorni dopo le presentazioni. Queste conferenze offrono a Sensei Biotherapeutics l'opportunità di mostrare i propri progressi nello sviluppo di terapie per il cancro di nuova generazione a investitori e professionisti del settore.
Sensei Biotherapeutics (Nasdaq: SNSE), una empresa de inmunooncología en etapa clínica, ha anunciado su participación en dos conferencias próximas en septiembre de 2024. La compañía presentará en la 26ª Conferencia Anual de Inversión Global de H.C. Wainwright el 9 de septiembre a las 7:00 a.m. ET, ofreciendo una presentación corporativa. Además, Sensei participará en una charla informal en la 2024 Cantor Fitzgerald Global Healthcare Conference el 18 de septiembre a las 2:30 p.m. ET.
Ambos eventos serán accesibles a través de un webcast en la sección de Inversores del sitio web de Sensei, con repeticiones disponibles durante aproximadamente 90 días después de las presentaciones. Estas conferencias brindan a Sensei Biotherapeutics oportunidades para mostrar su progreso en el desarrollo de terapias contra el cáncer de nueva generación a inversores y profesionales de la industria.
센세이 생명과학 (Nasdaq: SNSE)는 임상 단계의 면역 온콜로지 회사로, 2024년 9월에 예정된 두 가지 회의에 참가한다고 발표했습니다. 이 회사는 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에서 9월 9일 오전 7시 ET에 기업 발표를 진행할 예정입니다. 또한, 센세이는 2024 캔토르 피츠제럴드 글로벌 헬스케어 회의에서 9월 18일 오후 2시 30분 ET에 파이어사이드 채팅에 참여할 것입니다.
두 이벤트는 센세이 웹사이트의 투자자 섹션을 통해 웹캐스트로 확인할 수 있으며, 발표 후 약 90일 동안 재생이 가능합니다. 이러한 회의는 센세이 생명과학이 차세대 암 치료제를 발전시키는 과정에서 투자자와 업계 전문가들에게 그들의 진행 상황을 보여줄 수 있는 기회를 제공합니다.
Sensei Biotherapeutics (Nasdaq: SNSE), une entreprise d'immuno-oncologie en phase clinique, a annoncé sa participation à deux conférences à venir en septembre 2024. L'entreprise présentera lors de la 26ème Conférence Annuelle Globale d'Investissement de H.C. Wainwright le 9 septembre à 7h00 ET, avec une présentation de l'entreprise. De plus, Sensei participera à une discussion informelle lors de la 2024 Cantor Fitzgerald Global Healthcare Conference le 18 septembre à 14h30 ET.
Les deux événements seront accessibles par webcast dans la section Investisseurs du site web de Sensei, avec des replays disponibles pendant environ 90 jours après les présentations. Ces conférences offrent à Sensei Biotherapeutics des opportunités de montrer leurs progrès dans le développement de thérapies anticancéreuses de nouvelle génération aux investisseurs et aux professionnels du secteur.
Sensei Biotherapeutics (Nasdaq: SNSE), ein Unternehmen für immunonkologische Forschung in der klinischen Phase, hat die Teilnahme an zwei bevorstehenden Konferenzen im September 2024 angekündigt. Das Unternehmen wird am 9. September um 7:00 Uhr ET bei der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright eine Unternehmenspräsentation halten. Darüber hinaus wird Sensei am 18. September um 14:30 Uhr ET an einem informellen Gespräch bei der 2024 Cantor Fitzgerald Global Healthcare Conference teilnehmen.
Beide Veranstaltungen werden über einen Webcast im Investor-Bereich der Webseite von Sensei zugänglich sein, wobei die Wiederholungen etwa 90 Tage nach den Präsentationen verfügbar sind. Diese Konferenzen bieten Sensei Biotherapeutics die Möglichkeit, ihre Fortschritte bei der Entwicklung von Krebsmedikamenten der nächsten Generation Investoren und Branchenprofis vorzustellen.
- None.
- None.
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024:
H.C. Wainwright 26th Annual Global Investment Conference
Corporate Presentation
Monday, September 9, 2024, at 7:00 a.m. ET.
Virtual and New York, NY
2024 Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Wednesday, September 18, 2024, at 2:30 p.m. ET.
New York, NY
Webcasts of both presentations will be available on the Investors section of the Sensei website. Replays will be on the website for approximately 90 days following the events.
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
When is Sensei Biotherapeutics (SNSE) presenting at the H.C. Wainwright Global Investment Conference?
What type of presentation will Sensei Biotherapeutics (SNSE) give at the Cantor Fitzgerald Global Healthcare Conference?
How long will the webcasts of Sensei Biotherapeutics' (SNSE) presentations be available?
Where can investors access the webcasts of Sensei Biotherapeutics' (SNSE) conference presentations?
